521PMulticenter phase II study of biweekly XELIRI plus...

Annals of Oncology 2017 / 09 Vol. 28; Iss. suppl_5

521PMulticenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

Mori, Y., Suzuki, N., Nagasaka, T., Tanioka, H., Iwamoto, Y., Neki, Y., Yamatsuji, T., Kobayashi, M., Nakajima, M., Ojima, Y., Ikeda, S., Kawamoto, K., Shinozaki, K., Tsuji, A., Hinoi, T., Yamaguchi,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx393.047
Date:
September, 2017
File:
PDF, 48 KB
english, 2017
Conversion to is in progress
Conversion to is failed